Redmile Group’s Xeris Biopharma Holdings XERS Stock Holding History

Redmile Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-451,099	Closed	-$3.67M	–	42
2025 Q3	$3.67M	Hold	451,099	–	–	0.36%	31
2025 Q2	$2.11M	Hold	451,099	–	–	0.22%	42
2025 Q1	$2.48M	Hold	451,099	–	–	0.23%	48
2024 Q4	$1.53M	Sell	451,099 -595,488	-57%	-$1.92M	0.11%	57
2024 Q3	$2.98M	Hold	1,046,587	–	–	0.18%	54
2024 Q2	$2.35M	Hold	1,046,587	–	–	0.14%	56
2024 Q1	$2.31M	Hold	1,046,587	–	–	0.08%	71
2023 Q4	$2.46M	Hold	1,046,587	–	–	0.09%	61
2023 Q3	$1.95M	Hold	1,046,587	–	–	0.09%	60
2023 Q2	$2.74M	Hold	1,046,587	–	–	0.11%	64
2023 Q1	$1.71M	Hold	1,046,587	–	–	0.07%	68
2022 Q4	$1.39M	Hold	1,046,587	–	–	0.06%	65
2022 Q3	$1.63M	Hold	1,046,587	–	–	0.06%	66
2022 Q2	$1.61M	Hold	1,046,587	–	–	0.06%	66
2022 Q1	$2.68M	Hold	1,046,587	–	–	0.08%	64
2021 Q4	$3.07M	Sell	1,046,587 -312,238	-23%	-$674K	0.07%	66
2021 Q3	$3.33M	Hold	1,358,825	–	–	0.06%	71
2021 Q2	$5.53M	Sell	1,358,825 -353,479	-21%	-$1.35M	0.08%	79
2021 Q1	$7.72M	Sell	1,712,304 -685,137	-29%	-$3.7M	0.11%	77
2020 Q4	$11.8M	Hold	2,397,441	–	–	0.14%	71
2020 Q3	$14.2M	Hold	2,397,441	–	–	0.26%	62
2020 Q2	$6.38M	Sell	2,397,441 -560,000	-19%	-$1.95M	0.12%	72
2020 Q1	$5.77M	Sell	2,957,441 -43,200	-1%	-$186K	0.16%	59
2019 Q4	$21.2M	Hold	3,000,641	–	–	0.51%	48
2019 Q3	$29.5M	Hold	3,000,641	–	–	0.99%	31
2019 Q2	$34.3M	Hold	3,000,641	–	–	0.97%	31
2019 Q1	$30.1M	Buy	3,000,641 +588,000	+24%	+$7.53M	0.88%	39
2018 Q4	$41M	Buy	2,412,641 +1	+0%	+$20	1.65%	20
2018 Q3	$42.4M	Sell	2,412,640 -2	-0%	-$43	1.3%	27
2018 Q2	$45.8M	Buy	+2,412,642	New	+$46.9M	1.56%	24

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group's XERS Position: Q4 2025 in Review

Redmile Group sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 451,099 shares — an estimated $3.67M sold.

Redmile Group first reported a position in XERS in Q2 2018 and held it in 30 quarters. The position peaked at $45.8M in Q2 2018. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

Redmile Group reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
Redmile Group sold 451,099 Xeris Biopharma Holdings shares in Q4 2025, an estimated $3.67M.
Redmile Group first reported a position in Xeris Biopharma Holdings in Q2 2018 and held it in 30 quarters.
Redmile Group's Xeris Biopharma Holdings position peaked at $45.8M in Q2 2018.
225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.